Talazoparib companion diagnostic - Myriad GeneticsAlternative Names: BMN-673 companion diagnostic; BRACAnalysis (Talazoparib); BRACAnalysis CDx (Talazoparib); Talazoparib - BRACAnalysis; Talazoparib - BRACAnalysis CDx
Latest Information Update: 26 Mar 2015
At a glance
- Originator Myriad Genetics
- Developer BioMarin Pharmaceutical; Myriad Genetics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 01 Oct 2013 Phase-III clinical trials in Breast cancer (Diagnosis) in USA (unspecified route)